September 19, 2024 04:06 PM EDT

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

Max Bayer

Pharma Reporter

Aligos Therapeutics’ oral treatment for an advanced form of fatty liver disease reported positive results in a Phase 2 trial, showing it was effective at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Vertex makes money from sickle cell therapy Casgevy

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend